



Contact: Rehab AlJamal-Naylor
Tel. 017919-621 733
Email: r.aljamal.naylor@avipero.com

FOR IMMEDIATE PRESS RELEASE

Wednesday, 13th July 2016.

AVIPERO Issued Key US patent on the Utility of Beta1 Integrin.

EDINBURGH, SCOTLAND-Wed, 13 July, 2016-----AVIPERO (Registered in Scotland SC353945) announced today that it has been issued the US patent from the USPTO titled "Tissue Repair by Modulation of Beta-1 Integrin Biological Function" claiming use of beta1 integrin for tissue repair. The patent was granted on the above mentioned application on 5 July 2016 having the patent no. 9,382,322. The patent will remain in force until 2025.

About AVIPERO Ltd.

AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This now also includes advanced metastatic cancers in addition to Parkinson's disease (PD) and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio.

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO's dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Dr. Rehab AlJamal-Naylor
AVIPERO Ltd
Director and CSO,
+44(0)7919-621-733
info@avipero.com
www.avipero.com